Starting DDAVP Causes Dangerous Salt Loss via 50-Fold ANP Surge in Wolfram Syndrome
Initiating desmopressin (DDAVP) for diabetes insipidus in Wolfram syndrome caused abrupt volume expansion, 50-fold elevated ANP and elevated BNP, leading to life-threatening renal salt wasting — rescued by fludrocortisone.
Quick Facts
What This Study Found
DDAVP initiation in untreated Wolfram DI caused ANP elevation ×50 and BNP ×2-4, blocking zona glomerulosa steroidogenesis, causing secondary mineralocorticoid deficiency and acute hyponatremia from RSW. Fludrocortisone 100-200 μg twice daily rescued electrolytes within 48 hours.
Key Numbers
ANP 50x elevated; BNP 2-4x elevated; fludrocortisone 100-200 μg BID; electrolytes normalized in 48h
How They Did This
Clinical case report. Two sisters (19 and 7 years) with Wolfram syndrome and untreated DI. Initiated oral melt DDAVP. ANP and BNP levels measured. Electrolyte monitoring. Fludrocortisone treatment and response documented.
Why This Research Matters
This identifies a potentially life-threatening complication when starting a common peptide drug (DDAVP) for diabetes insipidus. The natriuretic peptide-mediated mechanism explains why this happens and how to prevent or treat it.
The Bigger Picture
This case reveals how natriuretic peptide surges can cause dangerous electrolyte disturbances — a mechanism relevant beyond Wolfram syndrome. Any condition involving rapid volume expansion could trigger similar ANP/BNP-mediated salt wasting.
What This Study Doesn't Tell Us
Case report of two sisters (one family). Wolfram syndrome is extremely rare. The 50-fold ANP elevation may reflect the severity of untreated DI. Results may not generalize to milder volume expansion scenarios.
Questions This Raises
- ?Should ANP/BNP be routinely monitored when starting DDAVP for any form of diabetes insipidus?
- ?Could prophylactic fludrocortisone prevent this complication?
- ?Does this mechanism contribute to hyponatremia in other conditions involving rapid fluid administration?
Trust & Context
- Key Stat:
- 50-fold ANP surge DDAVP-induced volume expansion caused a 50-fold increase in ANP, blocking aldosterone production and causing potentially fatal sodium loss — rescuable with fludrocortisone
- Evidence Grade:
- Low evidence (case report of 2 patients). Important for clinical awareness despite limited sample. Mechanism is physiologically sound.
- Study Age:
- Published 2021. Important safety alert for clinicians initiating DDAVP in untreated diabetes insipidus.
- Original Title:
- Lessons from Wolfram Syndrome: Initiation of DDAVP Therapy Causes Renal Salt Wasting Due to Elevated ANP/BNP Levels, Rescued by Fludrocortisone Treatment.
- Published In:
- Indian journal of pediatrics, 88(6), 582-585 (2021)
- Authors:
- Kleanthous, Kleanthis, Maratou, Eirini(2), Spyropoulou, Dora, Dermitzaki, Eleni, Papadimitriou, Anastasios, Zoupanos, George, Moutsatsou, Paraskevi, Mastorakos, George, Urano, Fumihiko, Papadimitriou, Dimitrios T
- Database ID:
- RPEP-05504
Evidence Hierarchy
Describes what happened to one person or a small group.
What do these levels mean? →Frequently Asked Questions
What went wrong when these patients started DDAVP?
DDAVP stopped their massive urine output suddenly, causing rapid water retention. The body responded by releasing huge amounts of ANP (a peptide that makes the kidneys excrete sodium), which caused dangerous sodium loss. Fludrocortisone blocked this salt-wasting response.
What are ANP and BNP?
Atrial and brain natriuretic peptides are hormones released by the heart when it's stretched by excess fluid volume. They cause the kidneys to excrete sodium and water. When released in massive amounts (50-fold in this case), they can cause life-threatening electrolyte imbalances.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-05504APA
Kleanthous, Kleanthis; Maratou, Eirini; Spyropoulou, Dora; Dermitzaki, Eleni; Papadimitriou, Anastasios; Zoupanos, George; Moutsatsou, Paraskevi; Mastorakos, George; Urano, Fumihiko; Papadimitriou, Dimitrios T. (2021). Lessons from Wolfram Syndrome: Initiation of DDAVP Therapy Causes Renal Salt Wasting Due to Elevated ANP/BNP Levels, Rescued by Fludrocortisone Treatment.. Indian journal of pediatrics, 88(6), 582-585. https://doi.org/10.1007/s12098-020-03538-y
MLA
Kleanthous, Kleanthis, et al. "Lessons from Wolfram Syndrome: Initiation of DDAVP Therapy Causes Renal Salt Wasting Due to Elevated ANP/BNP Levels, Rescued by Fludrocortisone Treatment.." Indian journal of pediatrics, 2021. https://doi.org/10.1007/s12098-020-03538-y
RethinkPeptides
RethinkPeptides Research Database. "Lessons from Wolfram Syndrome: Initiation of DDAVP Therapy C..." RPEP-05504. Retrieved from https://rethinkpeptides.com/research/kleanthous-2021-lessons-from-wolfram-syndrome
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.